[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592634":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":33,"locations":42,"responsibleParty":60,"collaborators":24,"id":62,"slug":24,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":24,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":24,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":24,"overallStatus":45,"whyStopped":24,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"First Affiliated Hospital of Fujian Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"68Ga-dPNE PET\u002FCT","EXPERIMENTAL","Intravenous injection of 68Ga-dPNE. 68Ga-dPNE PET\u002FCT will be used to detect tumors.",[13],"Drug: 68Ga-dPNE",{"label":15,"type":10,"description":16,"interventionNames":17},"18F-FDG PET\u002FCT","Intravenous injection of 18F-FDG. 18F-FDG PET\u002FCT will be used to detect tumors.",[18],"Drug: 18F-FDG",[20,25],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG","68Ga-dPNE",[9],null,{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"18F-FDG","Intravenous injection of 18F-FDG.18F-FDG PET\u002FCT will be used to detect tumors.",[15],[30],{"name":31,"affiliation":5,"role":32},"Weibing Miao, MD","PRINCIPAL_INVESTIGATOR",[34,38],{"name":31,"role":35,"phone":36,"phoneExt":24,"email":37},"CONTACT","+86-0591-87981618","miaoweibing@126.com",{"name":39,"role":35,"phone":40,"phoneExt":24,"email":41},"Rong Lin, MD","+86-0591-87981619","linrong1214@foxmail.com",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"The First Affiliated Hospital of Fujian Medical University","RECRUITING","Fuzhou","Fujian","350005","China","CN",{"type":52,"coordinates":53},"Point",[54,55],119.30611,26.06139,{"lat":55,"lon":54},[58,59],{"name":31,"role":35,"phone":36,"phoneExt":24,"email":37},{"name":39,"role":35,"phone":40,"phoneExt":24,"email":41},{"type":61,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100592634",false,"NCT06995976","Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73","Inclusion Criteria:\n\nSigned informed consent and be able to follow up.\n\nExclusion Criteria:\n\nPregnant or lactational women; who suffered from severe hepatic and renal insufficiency.",true,"ALL","18 Years","90 Years",{"count":72,"type":73},30,"ESTIMATED","INTERVENTIONAL",[76],"EARLY_PHASE1","As a new CD73-targeted PET radiotracer, 68Ga-dPNE, is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-dPNE in human volunteers. Furthermover, we conducted a comparative analysis of 68Ga-dPNE and 18F-FDG imaging to assess both the radiation dosimetry and diagnostic efficacy of 68Ga-dPNE.",[79],"Malignant Tumour","2025-05-21",{"date":82,"type":83},"2025-05-30","ACTUAL",{"date":85,"type":83},"2025-03-01",{"date":87,"type":73},"2026-03-01",{"name":5,"class":6},1]